|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study显示文摘 | Thomas J. Lynch Igor Bondarenko Alexander Luft Piotr Serwatowski Fabrice Barlesi Raju Chacko Martin Sebastian Joel Neal Haolan Lu Jean-Marie Cuillerot Martin Reck | 2012 | Journal of Clinical Oncology2012，，17： | 2 |
| 2 | A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies显示文摘 | Chris Twelves Martin Reck Alan Anthoney Ulrich Gatzemeier Stan Kaye | 2003 | Cancer Chemotherapy and Pharmacology2003，，4： | 1 |
| 3 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial显示文摘 | Martin Reck Rolf Kaiser Anders Mellemgaard Jean-Yves Douillard Sergey Orlov Maciej Krzakowski Joachim von Pawel Maya Gottfried Igor Bondarenko Meilin Liao Claudia-Nanette Gann José Barrueco Birgit Gaschler-Markefski Silvia Novello | 2014 | Lancet Oncology2014，，2： | 1 |
| 4 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study显示文摘 | Thomas J. Lynch Igor Bondarenko Alexander Luft Piotr Serwatowski Fabrice Barlesi Raju Chacko Martin Sebastian Joel Neal Haolan Lu Jean-Marie Cuillerot Martin Reck | 2012 | Journal of Clinical Oncology2012，，17： | 1 |
| 5 | An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases 显示文摘 | Sandier Alan Hirsh Vera Reck Martin | 2012 | Lung Cancer2012，78，1： | 1 |
| 6 | A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer显示文摘 | Wolfgang H.W. Schuette Andreas Groeschel Martin Sebastian Stefan Andreas Thomas Mueller Folker Schneller Sylvia Guetz Corinna Eschbach Sabine Bohnet Monika I. Leschinger Martin Reck | 2013 | Clinical Lung Cancer2013，，： | 1 |
| 7 | Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis显示文摘 | Sanjay Popat Anders Mellemgaard Kyle Fahrbach Alison Martin Maria Rizzo Rolf Kaiser Ingolf Griebsch Martin Reck | 2015 | Future Oncol2015，，3： | 1 |
| 8 | Hyponatremia as prognostic factor in small cell lung cancer – A retrospective single institution analysis显示文摘 | Andreas Hermes Benjamin Waschki Martin Reck | 2012 | Respiratory Medicine2012，，6： | 1 |
| 9 | Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial显示文摘 | Cesare Gridelli Eckhard Kaukel Vanessa Gregorc Maria Rita Migliorino Thomas R. Müller Christian Manegold Adolfo Favaretto Andrea Martoni Orazio Caffo Alexander Schmittel Antonio Rossi Francesca Russo Patrick Peterson María Mu?oz Martin Reck | 2007 | Journal of Thoracic Oncology2007，，3： | 1 |
| 10 | PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer显示文摘 | Luis G. Paz-Ares Filippo de Marinis Mircea Dediu Michael Thomas Jean-Louis Pujol Paolo Bidoli Olivier Molinier Tarini Prasad Sahoo Eckart Laack Martin Reck Jesús Corral Symantha Melemed William John Nadia Chouaki Annamaria H. Zimmermann Carla Visseren-Gru | 2013 | Journal of Clinical Oncology2013，，23： | 1 |
| 11 | Characteristics, treatment patterns and outcomes of patients with small cell lung cancer—A retrospective single institution analysis显示文摘 | Andreas Hermes Benjamin Waschki Ulrich Gatzemeier Martin Reck | 2010 | Lung Cancer2010，，3： | 1 |
| 12 | Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, random显示文摘 | Luis Paz-Ares Filippo de Marinis Mircea Dediu Michael Thomas Jean-Louis Pujol Paolo Bidoli Olivier Molinier Tarini Prasad Sahoo Eckart Laack Martin Reck Jesús Corral Symantha Melemed William John Nadia Chouaki Annamaria H Zimmermann Carla Visseren-Grul Ce | 2012 | Lancet Oncology2012，，3： | 1 |
| 13 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial显示文摘 | Martin Reck Rolf Kaiser Anders Mellemgaard Jean-Yves Douillard Sergey Orlov Maciej Krzakowski Joachim von Pawel Maya Gottfried Igor Bondarenko Meilin Liao Claudia-Nanette Gann José Barrueco Birgit Gaschler-Markefski Silvia Novello | 2014 | Lancet Oncology2014，，2： | 1 |
| 14 | 吉非替尼与多西紫杉醇在化疗后非小细胞肺癌患者中的疗效对比(INTEREST):一项随机Ⅲ期临床试验显示文摘背景两项在既往接受过治疗的晚期非小细胞肺癌患者中进行的Ⅱ期临床试验结果表明,吉非替尼的疗效优于化疗,且毒副作用更小:局部晚期或转移性非小细胞肺癌患者在接受以铂类药物为基础的化疗后,继续使用吉非替尼和多西紫杉醇进行治疗,观察并比较两类药物的疗效:方法2004年3月1日至2006年2月17日,采用开放标记的Ⅲ期临床研究的方法,在全球24个国家的149家中心招募受试者。1466例晚期非小细胞肺癌患者在接受铂类药物化疗后(铂类药物化疗至少1个疗程),经随机分组,分别接受吉非替尼(250mg口服,每日1次;n=733)或多西紫杉醇(75mg/m^2静脉注射,1h注射完毕,每3周1次;n=733)治疗,并保持两组间样本数量的动态平衡。本研究的主要目的是采用协同主要分析法,比较两组间的存活情况,以此评估吉非替尼在总体符合方案人群中的非劣效性,在意向治疗人群高表皮生长因子受体(EGFR)基因拷贝数患者中的优效性。本临床研究在ClinicalTrials.gov上注册,编号为NCT00076388。结果本研究分析了两种治疗方案下的共计1433例患者(吉非替尼组723例,多西紫杉醇组710例)。总体存活情况确认了吉非替尼相对于多西紫杉醇的非劣效性(事件593例Fs576例,HR1.020,96%C10.905~1.150,达到预定非劣效性标准;中位存活时间7.6月 vs8.0月):具有高EGFR基因拷贝数的患者(85例 vs 89例)未显示出吉非替尼治疗的优效性证据(事件72例vs 71例,HR1.09,95%C10.78-1.51,P=0.62;中位存活时间8.4个月Fs7.5个月)?在吉非替尼治疗组中,最常见的不良事件包括皮疹或痤疮[360例(49%)vs 73例(10%)]以及腹泻[255例(35%)vs 177例(25%)];然而,在多西紫杉醇治疗组中,中性粒细胞减少症[35例(5%)vs 514例(74%)]、乏力不适[182例(25%)vs 334例(47%)]以及脱发[23例(3%)vs 254例(36%)1是最常见的不良事件。结论INTEREST研究确立了吉非替尼与多西紫杉醇相比在存活率方面的非劣效性,提示吉非替尼对于既往接受过治疗的晚期非小细胞肺癌患者是一项有效的治疗措施。 | Edward SKim Vera Hirsh Tony Mok Mark A Socinski Radj Gervais Yi-Long Wu Long-Yun Li Claire L Watkins Mark V Sellers Elizabeth S Lowe Yan Sun Mei-Lin Liao Kell Osterlind Martin Reck Alison A Armour Frances A Shepherd Scott M Lippman lean-Yves Douillard | 2009 | 世界临床医学2009，，7： | 0 |
| 15 | Insights into CODE-DE–Germany’s Copernicus data and exploitation platform显示文摘This article presents and analyses the modular architecture and capabilities of CODE-DE(Copernicus Data and Exploitation Platform–Deutschland,www.code-de.org),the integrated German operational environment for accessing and processing Copernicus data and products,as well as the methodology to establish and operate the system.Since March 2017,CODE-DE has been online with access to Sentinel-1 and Sentinel-2 data,to Sentinel-3 data shortly after this time,and since March 2019 with access to Sentinel-5P data.These products are available and accessed by 1,682 registered users as of March 2019.During this period 654,895 products were downloaded and a global catalogue was continuously updated,featuring a data volume of 814 TByte based on a rolling archive concept supported by a reload mechanism from a long-term archive.Since November 2017,the element for big data processing has been operational,where registered users can process and analyse data themselves specifically assisted by methods for value-added product generation.Utilizing 195,467 core and 696,406 memory hours,982,948 products of different applications were fully automatically generated in the cloud environment and made available as of March 2019.Special features include an improved visualization of available Sentinel-2 products,which are presented within the catalogue client at full 10 m resolution. | Tobias Storch Christoph Reck Stefanie Holzwarth Bert Wiegers Nico Mandery Ulrich Raapea Christian Strobl Rouven Volkmann Martin Böttcher Andreas Hirner Johanna Senft Nicolae Plesia Thomas Kukuk Stephan Meissl Jens-Rainer Felske Thomas Heege Vanessa Keuck Michael Schmidt Helmut Staudenrausch | 2019 | Big Earth Data2019，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员